The Experts below are selected from a list of 16446 Experts worldwide ranked by ideXlab platform
Sung Ho Ghil - One of the best experts on this subject based on the ideXlab platform.
-
prevention of postsurgical Tissue adhesion by anti inflammatory drug loaded pluronic mixtures with sol gel transition behavior
Journal of Biomedical Materials Research Part A, 2005Co-Authors: Se Heang Oh, Kyu Sang Song, Sung Ho GhilAbstract:Sol–gel transition temperature-controllable Pluronic F127/F68 mixtures including mildly crosslinked alginate and nonsteroidal anti-inflammatory drug (ibuprofen) were prepared to evaluate their potential as Tissue adhesion barrier gels. The sol–gel transition temperatures of the Pluronic mixtures could be controlled by adjusting F127/F68 ratio and polymer concentration. The mildly crosslinked alginate with still flow property provided the residence stability of Pluronic mixture gels in the body. Ibuprofen was loaded in Pluronic mixtures to reduce inflammatory response in the body and, thus, to prevent Tissue adhesion. The gelation temperatures of the Pluronic mixtures were not affected by the alginate but lowered by the addition of ibuprofen. The in vitro drug release behavior and in vivo Peritoneal Tissue adhesion of the Pluronic mixtures with the sol–gel transition just below body temperatures were investigated. The drug release behavior from the ibuprofen (1 wt%)-loaded Pluronic mixture gels at 37°C was examined using a membrane-less dissolution model. The drug in the mixture gels was released continuously up to about 45–65% of the total loading amount during the first 7 days. For in vivo evaluation of Tissue anti-adhesion potential, the Pluronic mixtures with/without drug were coated on the Peritoneal wall defects of rats and their Tissue adhesion extents and Tissue reactions (inflammatory response, granulation Tissue formation, and toxicity in organs) were compared. It was observed that ibuprofen has a positive effect for the Peritoneal Tissue anti-adhesion. The Pluronic F127/F68/alginate/ibuprofen mixture gel (25 wt% of F127/F68 [7/3], 1 wt% ibuprofen) was highly effective for the prevention of Peritoneal Tissue adhesion and showed a relatively low inflammatory response and non-toxicity, and thus can be a good candidate material as a coatable or injectable Tissue adhesion barrier gel. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res 72A: 306–316, 2005
-
Prevention of postsurgical Tissue adhesion by anti‐inflammatory drug‐loaded pluronic mixtures with sol–gel transition behavior
Journal of biomedical materials research. Part A, 2005Co-Authors: Jin Kyeong Kim, Kyu Sang Song, Sung Ho Ghil, Seung Moo Noh, Soon Hong Yuk, Jin Ho LeeAbstract:Sol-gel transition temperature-controllable Pluronic F127/F68 mixtures including mildly crosslinked alginate and nonsteroidal anti-inflammatory drug (ibuprofen) were prepared to evaluate their potential as Tissue adhesion barrier gels. The sol-gel transition temperatures of the Pluronic mixtures could be controlled by adjusting F127/F68 ratio and polymer concentration. The mildly crosslinked alginate with still flow property provided the residence stability of Pluronic mixture gels in the body. Ibuprofen was loaded in Pluronic mixtures to reduce inflammatory response in the body and, thus, to prevent Tissue adhesion. The gelation temperatures of the Pluronic mixtures were not affected by the alginate but lowered by the addition of ibuprofen. The in vitro drug release behavior and in vivo Peritoneal Tissue adhesion of the Pluronic mixtures with the sol-gel transition just below body temperatures were investigated. The drug release behavior from the ibuprofen (1 wt%)-loaded Pluronic mixture gels at 37 degrees C was examined using a membrane-less dissolution model. The drug in the mixture gels was released continuously up to about 45-65% of the total loading amount during the first 7 days. For in vivo evaluation of Tissue anti-adhesion potential, the Pluronic mixtures with/without drug were coated on the Peritoneal wall defects of rats and their Tissue adhesion extents and Tissue reactions (inflammatory response, granulation Tissue formation, and toxicity in organs) were compared. It was observed that ibuprofen has a positive effect for the Peritoneal Tissue anti-adhesion. The Pluronic F127/F68/alginate/ibuprofen mixture gel (25 wt% of F127/F68 [7/3], 1 wt% ibuprofen) was highly effective for the prevention of Peritoneal Tissue adhesion and showed a relatively low inflammatory response and non-toxicity, and thus can be a good candidate material as a coatable or injectable Tissue adhesion barrier gel.
Massimo Zucchetti - One of the best experts on this subject based on the ideXlab platform.
-
High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic IntraPeritoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation
Pharmaceutical Research, 2017Co-Authors: Federico Coccolini, Fabio Acocella, Lavinia Morosi, Stefano Brizzola, Matteo Ghiringhelli, Marco Ceresoli, Enrico Davoli, Luca Ansaloni, Maurizio D’incalci, Massimo ZucchettiAbstract:Purpose Paclitaxel (PTX) is currently used in combination with cisplatin for Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) for the treatment of Peritoneal carcinomatosis. Albumin-bound PTX is a promising new drug for HIPEC because of its easy solubility in aqueous perfusion medium and possibly because of the tendency of albumin to cross physiological barriers and accumulate in tumor Tissue. Methods We tested the feasibility of using nab- paclitaxel in rabbits treated by HIPEC for 60 min compared with the classical formulation at an equivalent PTX dose. Samples of perfusate and blood were collected at different time points and Peritoneal Tissues were collected at the end of perfusion. PTX concentrations were determined by HPLC. The depth of paclitaxel penetration through the Peritoneal barrier was assessed by mass spectrometry imaging. Results PTX after nab- paclitaxel treatment penetrated up to 0.63 mm in the Peritoneal wall, but after CRE-paclitaxel, it was not detectable in the peritoneum. Moreover, the Peritoneal concentration after nab- paclitaxel was five times that after paclitaxel classical formulation. Despite the high levels reached in the peritoneum, systemic exposure of PTX was low. Conclusions Our results show that nab- paclitaxel penetrates into the abdominal wall better than CRE-paclitaxel, in terms of effective penetration and Peritoneal Tissue concentration.
-
high penetration of paclitaxel in abdominal wall of rabbits after hyperthermic intraPeritoneal administration of nab paclitaxel compared to standard paclitaxel formulation
Pharmaceutical Research, 2017Co-Authors: Federico Coccolini, Fabio Acocella, Lavinia Morosi, Stefano Brizzola, Matteo Ghiringhelli, Marco Ceresoli, Enrico Davoli, Luca Ansaloni, Maurizio Dincalci, Massimo ZucchettiAbstract:Paclitaxel (PTX) is currently used in combination with cisplatin for Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) for the treatment of Peritoneal carcinomatosis. Albumin-bound PTX is a promising new drug for HIPEC because of its easy solubility in aqueous perfusion medium and possibly because of the tendency of albumin to cross physiological barriers and accumulate in tumor Tissue. We tested the feasibility of using nab-paclitaxel in rabbits treated by HIPEC for 60 min compared with the classical formulation at an equivalent PTX dose. Samples of perfusate and blood were collected at different time points and Peritoneal Tissues were collected at the end of perfusion. PTX concentrations were determined by HPLC. The depth of paclitaxel penetration through the Peritoneal barrier was assessed by mass spectrometry imaging. PTX after nab-paclitaxel treatment penetrated up to 0.63 mm in the Peritoneal wall, but after CRE-paclitaxel, it was not detectable in the peritoneum. Moreover, the Peritoneal concentration after nab-paclitaxel was five times that after paclitaxel classical formulation. Despite the high levels reached in the peritoneum, systemic exposure of PTX was low. Our results show that nab-paclitaxel penetrates into the abdominal wall better than CRE-paclitaxel, in terms of effective penetration and Peritoneal Tissue concentration.
Fabian R. Reimold - One of the best experts on this subject based on the ideXlab platform.
-
Transcriptional patterns in Peritoneal Tissue of encapsulating Peritoneal sclerosis, a complication of chronic Peritoneal dialysis.
PloS one, 2013Co-Authors: Fabian R. Reimold, Niko Braun, Zsuzsanna K. Zsengellér, Isaac E. Stillman, S. Ananth Karumanchi, Hakan R. Toka, Joerg Latus, Peter Fritz, Dagmar Biegger, Stephan SegererAbstract:Encapsulating Peritoneal sclerosis (EPS) is a devastating complication of Peritoneal dialysis (PD), characterized by marked inflammation and severe fibrosis of the peritoneum, and associated with high morbidity and mortality. EPS can occur years after termination of PD and, in severe cases, leads to intestinal obstruction and ileus requiring surgical intervention. Despite ongoing research, the pathogenesis of EPS remains unclear. We performed a global transcriptome analysis of Peritoneal Tissue specimens from EPS patients, PD patients without EPS, and uremic patients without history of PD or EPS (Uremic). Unsupervised and supervised bioinformatics analysis revealed distinct transcriptional patterns that discriminated these three clinical groups. The analysis identified a signature of 219 genes expressed differentially in EPS as compared to PD and Uremic groups. Canonical pathway analysis of differentially expressed genes showed enrichment in several pathways, including antigen presentation, dendritic cell maturation, B cell development, chemokine signaling and humoral and cellular immunity (P value
-
transcriptional patterns in Peritoneal Tissue of encapsulating Peritoneal sclerosis a complication of chronic Peritoneal dialysis
PLOS ONE, 2013Co-Authors: Fabian R. Reimold, Niko Braun, Zsuzsanna K. Zsengellér, Isaac E. Stillman, Hakan R. Toka, Ananth S KarumanchiAbstract:Encapsulating Peritoneal sclerosis (EPS) is a devastating complication of Peritoneal dialysis (PD), characterized by marked inflammation and severe fibrosis of the peritoneum, and associated with high morbidity and mortality. EPS can occur years after termination of PD and, in severe cases, leads to intestinal obstruction and ileus requiring surgical intervention. Despite ongoing research, the pathogenesis of EPS remains unclear. We performed a global transcriptome analysis of Peritoneal Tissue specimens from EPS patients, PD patients without EPS, and uremic patients without history of PD or EPS (Uremic). Unsupervised and supervised bioinformatics analysis revealed distinct transcriptional patterns that discriminated these three clinical groups. The analysis identified a signature of 219 genes expressed differentially in EPS as compared to PD and Uremic groups. Canonical pathway analysis of differentially expressed genes showed enrichment in several pathways, including antigen presentation, dendritic cell maturation, B cell development, chemokine signaling and humoral and cellular immunity (P value<0.05). Further interactive network analysis depicted effects of EPS-associated genes on networks linked to inflammation, immunological response, and cell proliferation. Gene expression changes were confirmed by qRT-PCR for a subset of the differentially expressed genes. EPS patient Tissues exhibited elevated expression of genes encoding sulfatase1, thrombospondin 1, fibronectin 1 and alpha smooth muscle actin, among many others, while in EPS and PD Tissues mRNAs encoding leptin and retinol-binding protein 4 were markedly down-regulated, compared to Uremic group patients. Immunolocalization of Collagen 1 alpha 1 revealed that Col1a1 protein was predominantly expressed in the submesothelial compact zone of EPS patient Peritoneal samples, whereas PD patient Peritoneal samples exhibited homogenous Col1a1 staining throughout the Tissue samples. The results are compatible with the hypothesis that encapsulating Peritoneal sclerosis is a distinct pathological process from the simple Peritoneal fibrosis that accompanies all PD treatment.
Hakan R. Toka - One of the best experts on this subject based on the ideXlab platform.
-
Transcriptional patterns in Peritoneal Tissue of encapsulating Peritoneal sclerosis, a complication of chronic Peritoneal dialysis.
PloS one, 2013Co-Authors: Fabian R. Reimold, Niko Braun, Zsuzsanna K. Zsengellér, Isaac E. Stillman, S. Ananth Karumanchi, Hakan R. Toka, Joerg Latus, Peter Fritz, Dagmar Biegger, Stephan SegererAbstract:Encapsulating Peritoneal sclerosis (EPS) is a devastating complication of Peritoneal dialysis (PD), characterized by marked inflammation and severe fibrosis of the peritoneum, and associated with high morbidity and mortality. EPS can occur years after termination of PD and, in severe cases, leads to intestinal obstruction and ileus requiring surgical intervention. Despite ongoing research, the pathogenesis of EPS remains unclear. We performed a global transcriptome analysis of Peritoneal Tissue specimens from EPS patients, PD patients without EPS, and uremic patients without history of PD or EPS (Uremic). Unsupervised and supervised bioinformatics analysis revealed distinct transcriptional patterns that discriminated these three clinical groups. The analysis identified a signature of 219 genes expressed differentially in EPS as compared to PD and Uremic groups. Canonical pathway analysis of differentially expressed genes showed enrichment in several pathways, including antigen presentation, dendritic cell maturation, B cell development, chemokine signaling and humoral and cellular immunity (P value
-
transcriptional patterns in Peritoneal Tissue of encapsulating Peritoneal sclerosis a complication of chronic Peritoneal dialysis
PLOS ONE, 2013Co-Authors: Fabian R. Reimold, Niko Braun, Zsuzsanna K. Zsengellér, Isaac E. Stillman, Hakan R. Toka, Ananth S KarumanchiAbstract:Encapsulating Peritoneal sclerosis (EPS) is a devastating complication of Peritoneal dialysis (PD), characterized by marked inflammation and severe fibrosis of the peritoneum, and associated with high morbidity and mortality. EPS can occur years after termination of PD and, in severe cases, leads to intestinal obstruction and ileus requiring surgical intervention. Despite ongoing research, the pathogenesis of EPS remains unclear. We performed a global transcriptome analysis of Peritoneal Tissue specimens from EPS patients, PD patients without EPS, and uremic patients without history of PD or EPS (Uremic). Unsupervised and supervised bioinformatics analysis revealed distinct transcriptional patterns that discriminated these three clinical groups. The analysis identified a signature of 219 genes expressed differentially in EPS as compared to PD and Uremic groups. Canonical pathway analysis of differentially expressed genes showed enrichment in several pathways, including antigen presentation, dendritic cell maturation, B cell development, chemokine signaling and humoral and cellular immunity (P value<0.05). Further interactive network analysis depicted effects of EPS-associated genes on networks linked to inflammation, immunological response, and cell proliferation. Gene expression changes were confirmed by qRT-PCR for a subset of the differentially expressed genes. EPS patient Tissues exhibited elevated expression of genes encoding sulfatase1, thrombospondin 1, fibronectin 1 and alpha smooth muscle actin, among many others, while in EPS and PD Tissues mRNAs encoding leptin and retinol-binding protein 4 were markedly down-regulated, compared to Uremic group patients. Immunolocalization of Collagen 1 alpha 1 revealed that Col1a1 protein was predominantly expressed in the submesothelial compact zone of EPS patient Peritoneal samples, whereas PD patient Peritoneal samples exhibited homogenous Col1a1 staining throughout the Tissue samples. The results are compatible with the hypothesis that encapsulating Peritoneal sclerosis is a distinct pathological process from the simple Peritoneal fibrosis that accompanies all PD treatment.
Federico Coccolini - One of the best experts on this subject based on the ideXlab platform.
-
High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic IntraPeritoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation
Pharmaceutical Research, 2017Co-Authors: Federico Coccolini, Fabio Acocella, Lavinia Morosi, Stefano Brizzola, Matteo Ghiringhelli, Marco Ceresoli, Enrico Davoli, Luca Ansaloni, Maurizio D’incalci, Massimo ZucchettiAbstract:Purpose Paclitaxel (PTX) is currently used in combination with cisplatin for Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) for the treatment of Peritoneal carcinomatosis. Albumin-bound PTX is a promising new drug for HIPEC because of its easy solubility in aqueous perfusion medium and possibly because of the tendency of albumin to cross physiological barriers and accumulate in tumor Tissue. Methods We tested the feasibility of using nab- paclitaxel in rabbits treated by HIPEC for 60 min compared with the classical formulation at an equivalent PTX dose. Samples of perfusate and blood were collected at different time points and Peritoneal Tissues were collected at the end of perfusion. PTX concentrations were determined by HPLC. The depth of paclitaxel penetration through the Peritoneal barrier was assessed by mass spectrometry imaging. Results PTX after nab- paclitaxel treatment penetrated up to 0.63 mm in the Peritoneal wall, but after CRE-paclitaxel, it was not detectable in the peritoneum. Moreover, the Peritoneal concentration after nab- paclitaxel was five times that after paclitaxel classical formulation. Despite the high levels reached in the peritoneum, systemic exposure of PTX was low. Conclusions Our results show that nab- paclitaxel penetrates into the abdominal wall better than CRE-paclitaxel, in terms of effective penetration and Peritoneal Tissue concentration.
-
high penetration of paclitaxel in abdominal wall of rabbits after hyperthermic intraPeritoneal administration of nab paclitaxel compared to standard paclitaxel formulation
Pharmaceutical Research, 2017Co-Authors: Federico Coccolini, Fabio Acocella, Lavinia Morosi, Stefano Brizzola, Matteo Ghiringhelli, Marco Ceresoli, Enrico Davoli, Luca Ansaloni, Maurizio Dincalci, Massimo ZucchettiAbstract:Paclitaxel (PTX) is currently used in combination with cisplatin for Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) for the treatment of Peritoneal carcinomatosis. Albumin-bound PTX is a promising new drug for HIPEC because of its easy solubility in aqueous perfusion medium and possibly because of the tendency of albumin to cross physiological barriers and accumulate in tumor Tissue. We tested the feasibility of using nab-paclitaxel in rabbits treated by HIPEC for 60 min compared with the classical formulation at an equivalent PTX dose. Samples of perfusate and blood were collected at different time points and Peritoneal Tissues were collected at the end of perfusion. PTX concentrations were determined by HPLC. The depth of paclitaxel penetration through the Peritoneal barrier was assessed by mass spectrometry imaging. PTX after nab-paclitaxel treatment penetrated up to 0.63 mm in the Peritoneal wall, but after CRE-paclitaxel, it was not detectable in the peritoneum. Moreover, the Peritoneal concentration after nab-paclitaxel was five times that after paclitaxel classical formulation. Despite the high levels reached in the peritoneum, systemic exposure of PTX was low. Our results show that nab-paclitaxel penetrates into the abdominal wall better than CRE-paclitaxel, in terms of effective penetration and Peritoneal Tissue concentration.